N@N

Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2009 American Society of Hematology Annua

_{//health-fitness.news-articles.net/content/2009/ .. e-2009-american-society-of-hematology-annua.html}
^{Published in Health and Fitness on Monday, November 30th 2009 at 13:05 GMT by Market Wire}  

SOUTH SAN FRANCISCO, CA--(Marketwire - November 30, 2009) - Cytokinetics, Incorporated (NASDAQ: [ CYTK ]) announced today that an abstract summarizing clinical trial data regarding SB-743921 is scheduled to be presented as a poster presentation at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division.

Poster Presentation at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition:

Abstract #1673 (Poster Board #I-695): "A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)" is scheduled to be displayed on Saturday, December 5, 2009 from 9:00 AM - 7:30 PM Central Time in the Lymphoma: Chemotherapy, Excluding Pre-Clinical Models Poster I Session. The poster will be presented by Owen A. O'Connor, M.D., Ph.D., New York University Langone Medical Center, New York, NY from 5:30 PM - 7:30 PM Central Time.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical development. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner for ispinesib and SB-743921. GSK-923295 is being developed by GlaxoSmithKline in collaboration with Cytokinetics. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at [ www.cytokinetics.com ].

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.